TherapeuticsMD (TXMD) stock price, revenue, and financials

TherapeuticsMD market cap is $399.4 m, and annual revenue was $49.65 m in FY 2019

$399.4 M

TXMD Mkt cap, 09-Jul-2020

$12.3 M

TherapeuticsMD Revenue Q1, 2020
TherapeuticsMD Gross profit (Q1, 2020)9.5 M
TherapeuticsMD Gross profit margin (Q1, 2020), %77.8%
TherapeuticsMD Net income (Q1, 2020)-56.8 M
TherapeuticsMD EBIT (Q1, 2020)-50.9 M
TherapeuticsMD Cash, 31-Mar-2020170.1 M
TherapeuticsMD EV481.5 M

TherapeuticsMD Revenue

TherapeuticsMD revenue was $49.65 m in FY, 2019

Embed Graph

TherapeuticsMD Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

2.1k721.7k819.2k1.0m1.5m2.1m2.3m2.8m3.8m4.2m4.5m4.8m5.2m4.9m4.4m5.5m4.0m4.3m4.4m3.8m3.8m3.5m3.9m6.1m23.7m12.3m

Cost of goods sold

336.1k372.4k306.8k380.3k463.6k648.4k830.7k893.0k1.1m1.0m1.0m1.2m1.1m1.1m1.2m659.6k681.7k700.8k633.6k454.2k699.1k762.8k1.2m1.4m2.7m

Gross profit

385.6k446.8k729.6k1.2m1.6m1.6m2.0m2.9m3.1m3.4m3.8m4.0m3.8m3.3m4.3m3.3m3.6m3.7m3.1m3.3m2.8m3.2m4.8m22.3m9.5m

Gross profit Margin, %

53%55%70%75%78%72%71%76%74%77%79%77%78%74%78%83%84%84%83%88%80%81%79%94%78%

R&D expense

412.0k833.3k1.3m1.6m1.7m4.1m5.9m8.2m14.9m18.2m24.2m16.4m15.1m13.8m14.7m7.7m8.7m6.4m7.0m6.8m6.7m6.3m5.0m4.1m3.3m

General and administrative expense

58.6k64.6k2.8m3.6m3.3m4.5m5.5m4.8m5.0m5.5m6.0m6.2m6.9m7.1m9.7m10.6m14.7m16.8m14.6m12.1m20.8m29.5m30.4m34.9m41.4m45.1m56.9m

Operating expense total

58.6k64.6k3.3m4.4m4.6m6.1m7.2m8.9m11.0m13.8m21.0m24.4m31.1m23.5m24.8m24.5m29.4m24.6m23.4m18.5m27.9m36.3m37.1m41.3m46.5m49.3m60.5m

Depreciation and amortization

14.6k8.0k10.6k32.4k13.1k14.1k12.7k13.6k14.3k16.5k19.6k24.3k40.5k49.7k53.2k54.1k59.6k65.6k73.3k106.9k115.1k142.0k262.0k

EBIT

(2.9m)(4.0m)(3.9m)(4.9m)(5.6m)(7.2m)(9.0m)(10.9m)(17.8m)(20.9m)(27.3m)(19.5m)(21.0m)(21.2m)(25.1m)(21.3m)(19.8m)(14.8m)(24.7m)(33.0m)(34.4m)(38.1m)(41.6m)(27.1m)(50.9m)

EBIT margin, %

(397%)(485%)(377%)(322%)(270%)(315%)(316%)(291%)(426%)(468%)(562%)(376%)(425%)(482%)(454%)(534%)(467%)(336%)(655%)(878%)(989%)(966%)(685%)(114%)(416%)

Interest expense

3.5k11.7k102.0k92.8k84.4k1.2m150.0436.0k232.3k27.8k15.6k28.4k28.1k30.4k44.2k117.2k112.4k129.8k152.9k167.3k314.6k197.1k1.2m1.4m13.6m4.9m

Interest income

5.0k3.5k12.0k9.2k9.2k9.4k9.8k2.6k2.8k41.6k114.3k109.9k3.9k3.8k167.3k314.6k334.2k809.0k688.7k486.6k703.7k335.5k

Pre tax profit

(57.1k)(74.2k)(13.3m)(11.9m)(4.3m)(6.4m)(6.0m)(7.7m)(9.2m)(10.9m)(17.8m)(20.9m)(27.2m)(19.5m)(20.9m)(21.1m)(25.0m)(21.2m)(19.7m)(14.7m)(24.4m)(33.2m)(35.6m)(39.5m)(55.2m)(32.0m)(56.8m)

Income tax expense

4.3k

Net Income

(57.1k)(78.5k)(13.3m)(11.9m)(4.3m)(6.4m)(6.0m)(7.7m)(9.2m)(10.9m)(17.8m)(20.9m)(27.2m)(19.5m)(20.9m)(21.1m)(25.0m)(21.2m)(19.7m)(14.7m)(24.4m)(33.2m)(35.6m)(39.5m)(55.2m)(32.0m)(56.8m)

TherapeuticsMD Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

126.4k1.6m54.2m51.4m64.7m131.5m127.1m161.6m160.8m

Accounts Receivable

26.7k606.6k1.7m2.2m3.0m4.3m11.1m24.4m

Prepaid Expenses

496.1k751.9k2.5m1.5m2.2m6.6m10.8m11.3m

Inventories

588.1k1.6m1.0m1.2m690.2k1.1m1.5m3.3m11.9m

Current Assets

1.2m4.5m59.4m56.2m70.7m139.4m139.6m186.8m208.4m

PP&E

70.1k65.7k61.3k63.3k198.6k437.1k472.7k2.5m

Total Assets

1.4m5.8m62.0m59.1m73.7m142.5m143.2m212.0m266.0m

Accounts Payable

306.5k1.6m2.1m6.3m3.1m7.4m4.1m22.7m19.2m

Dividends Payable

41.4k

Short-term debt

Current Liabilities

3.2m3.5m7.3m10.7m10.7m15.0m13.3m41.1m53.0m

Long-term debt

3.6m73.4m203.8m

Non-Current Liabilities

3.7m

Total Debt

3.6m73.4m203.8m

Total Liabilities

7.3m7.3m114.5m256.8m

Common Stock

83.0k99.8k145.0k156.1k177.9k216.4k240.5k271.2k

Additional Paid-in Capital

15.2m50.6m135.1m183.0m282.7m437.0m516.4m616.6m704.4m

Retained Earnings

(17.0m)(52.1m)(80.5m)(134.7m)(219.8m)(309.7m)(386.7m)(519.3m)(695.4m)

Total Equity

(1.7m)(1.4m)54.7m48.4m63.1m127.5m129.9m97.5m9.2m

Debt to Equity Ratio

-2.5 x0.8 x

Debt to Assets Ratio

0.6 x0.3 x

Financial Leverage

-0.8 x-4.1 x1.1 x1.2 x1.2 x1.1 x1.1 x2.2 x28.9 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

3.5k4.2k195.2k1.3m154.2k38.8m34.4m59.6m45.4m35.6m67.0m91.7m67.2m81.1m182.1m166.5m147.5m113.5m96.5m148.3m107.3m154.4m190.0m122.9m182.8m155.3m170.1m

Accounts Receivable

2.1k112.1k407.9k270.3k602.8k957.8k1.8m2.3m2.2m2.1m2.6m3.3m3.7m5.1m4.5m5.0m3.9m3.4m4.4m5.1m5.6m12.8m14.9m18.4m15.3m20.7m

Prepaid Expenses

2.0k999.0437.7k2.0k998.03.0k3.6m3.4m2.3m2.7m2.0m1.4m1.2m2.1m1.7m2.1m2.7m2.5m2.2m3.0m5.1m5.2m6.5m9.8m7.7m10.6m6.6m

Inventories

542.7k820.2k955.1k1.3m1.5m1.1m920.7k1.5m1.0m959.2k1.2m870.1k957.4k883.7k843.4k1.3m1.4m1.3m1.6m1.9m2.4m5.0m7.5m10.5m14.6m

Current Assets

5.5k7.3k1.3m3.5m2.2m42.9m40.5m65.9m51.0m41.8m72.2m96.7m73.0m87.8m189.8m174.0m156.1m121.3m103.5m157.0m119.2m167.1m211.7m152.6m216.5m191.8m212.0m

PP&E

87.9k107.4k95.1k83.9k76.5k47.4k77.9k76.7k69.6k56.4k64.6k56.7k264.7k444.4k460.5k511.1k483.7k448.1k425.5k403.6k381.9k668.6k1.4m2.3m2.3m

Total Assets

5.5k7.3k1.5m4.9m3.5m44.2m43.1m68.5m53.6m44.4m74.6m99.5m75.7m90.5m193.0m176.6m158.8m124.4m106.9m160.4m123.0m171.9m236.8m181.9m246.6m250.0m268.6m

Accounts Payable

2.5k15.2k607.8k692.1k1.0m1.8m2.0m2.5m3.1m2.3m5.6m6.2m5.8m5.3m3.4m3.0m4.2m6.1m8.1m4.2m6.3m11.4m11.4m25.4m19.5m24.1m28.7m

Dividends Payable

41.4k41.4k41.4k41.4k41.4k41.4k

Short-term debt

100.0k

Current Liabilities

356.6k437.0k2.6m2.5m4.4m4.2m4.6m6.4m6.8m6.9m11.0m11.1m11.7m11.7m9.6m9.3m12.5m14.1m13.3m10.9m15.7m21.2m29.3m45.0m41.9m67.3m61.6m

Long-term debt

2.2m3.1m3.3m73.1m73.3m76.2m196.6m203.9m252.2m

Non-Current Liabilities

3.4m73.1m73.3m252.2m

Total Debt

2.2m3.1m3.3m100.0k73.1m73.3m73.5m194.1m203.9m252.2m

Total Liabilities

356.6k437.0k4.8m5.6m7.8m4.2m4.6m6.4m6.8m6.9m11.8m12.7m12.9m9.3m12.5m94.4m102.5m121.2m238.5m271.2m313.8m

Common Stock

16.6k16.6k84.8k95.8k99.8k129.2k131.2k145.0k145.1k145.9k156.0k172.7k173.0k177.8k196.3k196.5k196.6k198.6k204.0k216.4k216.6k216.8k236.5k241.2k241.2k241.3k271.7k

Additional Paid-in Capital

1.7m1.7m26.8m41.3m50.3m98.3m102.8m134.1m136.3m138.0m181.9m243.2m245.7m279.7m423.9m428.9m433.0m441.0m444.0m514.5m518.1m521.6m613.9m619.2m621.9m624.5m706.8m

Retained Earnings

(2.0m)(2.1m)(30.3m)(42.1m)(46.4m)(58.5m)(64.5m)(72.2m)(89.7m)(100.6m)(118.4m)(155.6m)(182.9m)(202.3m)(240.8m)(261.9m)(286.9m)(330.9m)(350.6m)(365.2m)(411.1m)(444.3m)(479.9m)(558.8m)(614.0m)(646.0m)(752.3m)

Total Equity

(351.2k)(429.7k)(3.4m)(704.4k)(4.3m)39.9m38.5m62.1m46.8m37.5m63.6m87.7m63.0m77.6m183.4m167.2m146.4m110.3m93.6m149.5m107.3m77.5m134.2m60.7m8.1m(21.2m)(45.2m)

Debt to Equity Ratio

-0.7 x-4.4 x-0.8 x0 x0.9 x0.5 x1.2 x24 x

Debt to Assets Ratio

1.5 x0.6 x1 x0 x0.4 x0.3 x0.4 x0.8 x

Financial Leverage

0 x0 x-0.4 x-6.9 x-0.8 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.1 x1.2 x1.2 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x2.2 x1.8 x3 x30.5 x-11.8 x-5.9 x

TherapeuticsMD Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

556.4k477.8k(13.3m)(25.1m)(29.4m)(6.4m)(12.4m)(20.0m)(9.2m)(20.1m)(37.9m)(20.9m)(48.1m)(67.6m)(20.9m)(42.0m)(67.0m)(21.2m)(40.8m)(55.5m)(24.4m)(57.6m)(93.2m)(39.5m)(94.7m)(126.7m)(56.8m)

Depreciation and Amortization

14.6k29.1k44.0k8.0k18.6k51.0k13.1k27.2k39.9k13.6k27.9k44.4k19.6k43.9k84.3k49.7k102.9k156.9k59.6k125.2k198.5k106.9k222.0k364.0k1.0m

Accounts Receivable

2.1k85.3k396.2k276.8k(18.0k)(409.5k)(1.2m)(654.7k)(475.4k)(460.6k)(502.8k)(1.2m)(1.5m)(2.3m)(1.9m)(4.2m)580.9k1.1m106.5k(790.9k)(1.3m)(8.7m)(4.0m)(7.5m)(4.4m)3.9m

Inventories

(45.4k)232.2k367.1k277.3k109.2k467.6k122.9k(409.4k)31.7k222.9k(66.6k)312.1k(267.3k)(193.5k)(153.2k)(262.3k)(337.7k)(217.2k)(135.5k)(395.2k)(892.9k)(1.7m)(4.2m)(7.3m)(2.7m)

Accounts Payable

566.013.2k301.2k385.6k724.5k199.4k403.8k830.6k954.5k216.0k3.5m(91.9k)(508.5k)(1.0m)304.5k(86.8k)1.1m(1.2m)749.5k(3.2m)2.2m7.3m7.3m2.6m(3.2m)1.4m9.5m

Cash From Operating Activities

(147.0k)(202.2k)(2.5m)(5.2m)(8.4m)(3.5m)(10.7m)(15.9m)(8.7m)(18.8m)(30.2m)(19.1m)(44.0m)(62.4m)(19.4m)(34.7m)(53.5m)(20.5m)(38.7m)(55.4m)(19.6m)(44.6m)(78.7m)(38.2m)(88.7m)(114.9m)(39.1m)

Purchases of PP&E

(32.4k)(66.4k)(68.9k)(22.9k)(22.9k)(23.8k)(23.7k)(31.0k)(31.0k)(15.6k)(15.6k)(74.5k)(265.0k)(307.7k)(27.8k)(35.8k)(35.8k)(26.9k)(45.7k)(66.3k)(262.4k)(1.1m)(2.1m)(21.3k)

Cash From Investing Activities

(44.5k)(516.2k)(488.8k)(103.9k)(260.1k)(387.7k)(121.0k)(233.4k)(224.3k)(36.9k)(94.4k)(133.6k)(165.0k)(663.1k)(863.4k)(135.3k)(403.5k)(475.6k)(180.5k)(491.9k)(20.8m)(665.9k)(1.9m)(3.2m)(443.0k)

Short-term Borrowings

(779.0)(50.8k)(50.8k)(4.7m)500.0k(4.2m)

Long-term Borrowings

(400.0k)

Cash From Financing Activities

99.0k155.0k2.6m7.0m8.9m40.8m43.8m74.3m40.1k374.3k43.3m59.5m60.0m92.3m137.0m137.2m137.2m2.7m4.0m72.6m44.1k72.3m162.4m100.1k111.8m111.8m48.8m

Net Change in Cash

2.2k3.0k68.7k1.2m27.8k37.2m32.9m58.0m(8.8m)(18.6m)12.8m40.3m15.9m29.8m117.4m101.8m82.8m(18.0m)(35.1m)16.8m(19.8m)27.3m62.9m(38.7m)21.2m(6.3m)9.3m

Interest Paid

18.018.02.1k7.8k37.1k191.3k212.9k212.9k1.8m1.9m7.0m12.4m5.9m

Income Taxes Paid

4.3k

TherapeuticsMD Ratios

USDQ2, 2011

TherapeuticsMD Employee Rating

2.817 votes
Culture & Values
2.8
Work/Life Balance
3.4
Senior Management
3
Salary & Benefits
3.2
Career Opportunities
3
Source